Saturday , September 19 2020
Home / Managerial Econ / A Cheap Fast COVID-19 Screen

A Cheap Fast COVID-19 Screen

Summary:
Currently, those infected with COVID-19 can infect others a week before they know they are infectious. Suppose they knew a few days earlier. They could isolate themselves before they infect too many others. Current tests are too expensive, take too long to process, and are too few for this to work. But now recent emergency authorization will allowed Abbot Labs to supply a , 15 minute test. Abbott plans to produce 50 million per month, more than double the capacity of current tests.This test is has a higher false positive rate, requires a larger virus load, and is only approved for symptomatic cases. This last requirement is likely to be relaxed (or flaunted). This test is likely to be used as a screen.Kristian Andersen, an infectious-disease researcher at Scripps Research, noted that

Topics:
[email protected] (Michael Ward) considers the following as important:

This could be interesting, too:

[email protected] (Mike Shor) writes Voluntary Driver Monitoring and Auto Insurance

[email protected] (Michael Ward) writes “Ban-the-Box” versus Alternative Screens

[email protected] (Michael Ward) writes Adverse Selection into Privacy Protection

[email protected] (Michael Ward) writes Valentines Signals

Currently, those infected with COVID-19 can infect others a week before they know they are infectious. Suppose they knew a few days earlier. They could isolate themselves before they infect too many others. Current tests are too expensive, take too long to process, and are too few for this to work. But now recent emergency authorization will allowed Abbot Labs to supply a $5, 15 minute test. Abbott plans to produce 50 million per month, more than double the capacity of current tests.

This test is has a higher false positive rate, requires a larger virus load, and is only approved for symptomatic cases. This last requirement is likely to be relaxed (or flaunted). This test is likely to be used as a screen.

Kristian Andersen, an infectious-disease researcher at Scripps Research, noted that Abbott developed an app to go along with the test that would provide proof that a person had recently tested negative. To Andersen, this is clear evidence that “Abott didn’t just have symptomatic diagnostics in mind here, but also screening of asymptomatic people.”

The markets like the news too.



A Cheap Fast COVID-19 Screen

Leave a Reply

Your email address will not be published. Required fields are marked *